Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 3Phase 1 1

Status

Recruiting 5Active not recruiting 3

Sponsor Class

INDUSTRY 8NETWORK 1

Study Type

Interventional 8

Sponsor

Cancer Type

Genitourinary 4Gynecologic 3Breast 2Thoracic 1

Conditions

Prostatic Neoplasms 4Ovarian Neoplasms 3Endometrial Neoplasms 2Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 284Carboplatin 216Cisplatin 148Paclitaxel 145Gemcitabine 145Bevacizumab 117Pemetrexed 114Docetaxel 103Oxaliplatin 79Cyclophosphamide 79Dexamethasone 78durvalumab 77atezolizumab 77Fluorouracil 77Nivolumab 75130-nm albumin-bound paclitaxel 71Fulvestrant 68Capecitabine 64Injections 63Cetuximab 63Leucovorin 60Rituximab 56fludarabine 52Lenalidomide 49Prednisone 46venetoclax 43Irinotecan 43Letrozole 40enzalutamide 39tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × AZD5305 × 90 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

AstraZeneca

Phase 1 Active not recruiting
354 enrolled
Gynecologic

Ovarian Neoplasms

NCT07336446 2026-05-01

ANDROMEDA

AstraZeneca

Phase 1/2 Recruiting
300 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡